BEIJING, Oct. 28, 2011 /PRNewswire-Asia-FirstCall/ --
China Biologic Products, Inc. (Nasdaq: CBPO, "China Biologic" or
the "Company"), one of the leading plasma-based biopharmaceutical
companies in the People's Republic of
China, today announced that it has been selected as a
nominee for the 7th Annual Scrip Awards in the category of "Best
Company in an Emerging Market." The winner will be announced at the
awards ceremony on November 3, 2011
at the Grosvenor House hotel in London.
According to Scrip, the Scrip Awards recognize outstanding
performance across a range of business activities and provide the
biopharmaceutical industry with the opportunity to acknowledge and
applaud its highest achievers in all phases of the value chain. The
awards can recognize both corporate and individual achievement.
The awards are open to any company or individual in the
biopharmaceutical industry. A panel of 16 highly respected and
independent luminaries from the global biopharmaceutical industry
first votes a shortlist of nominees and then chooses the winners
for each category. Please visit
http://www.scripintelligence.com/awards/ for more information about
the awards. Of the six companies selected for the shortlist in the
category of "Best Company in an Emerging Market," China Biologic
was the only Chinese company to be included.
Mr. Chao Ming Zhao, the Company's
Chief Executive Officer, said, "We are very pleased to be a
candidate for one of our global industry's highest awards. We see
our nomination as an important international recognition for our
work and success over the past several years.
"We believe this nomination reflects the outstanding quality of
our existing products, our new product development process and
results, and our growth as one of the leading plasma-based
biopharmaceutical companies in China."
About China Biologic Products, Inc.
China Biologic Products, Inc., through its indirect
majority-owned subsidiaries, Shandong Taibang Biological Products
Co., Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd., and
its equity investment in Xi'an Huitian Blood Products Co., Ltd., is
one of the leading plasma-based biopharmaceutical companies in
China. The Company is a fully
integrated biologic products company with plasma collection,
production and manufacturing, research and development, and
commercial operations. Its plasma-based biopharmaceutical products
are irreplaceable during medical emergencies and are used for the
prevention and treatment of various diseases. China Biologic sells
its products to hospitals and other healthcare facilities in
China. Please visit its website at
www.chinabiologic.com for additional information.
Safe harbor statement
This release may contain certain "forward-looking statements"
relating to the business of China Biologic Products, Inc. and its
subsidiary companies. All statements, other than statements of
historical fact included herein are "forward-looking statements,"
including statements regarding: the ability of the Company to
achieve its commercial objectives; the business strategy, plans and
objectives of the Company and its subsidiaries; and any other
statements of non-historical information. These forward-looking
statements are often identified by the use of forward-looking
terminology such as "believes," "expects" or similar expressions,
and involve known and unknown risks and uncertainties. Although the
Company believes that the expectations reflected in these
forward-looking statements are reasonable, they do involve
assumptions, risks and uncertainties, and these expectations may
prove to be incorrect. Investors should not place undue reliance on
these forward-looking statements, which speak only as of the date
of this press release. The Company's actual results could differ
materially from those anticipated in these forward-looking
statements as a result of a variety of factors, including those
discussed in the Company's periodic reports that are filed with the
Securities and Exchange Commission and available on its website
(www.sec.gov). All forward-looking statements attributable to the
Company or persons acting on its behalf are expressly qualified in
their entirety by these factors. Other than as required under the
securities laws, the Company does not assume a duty to update these
forward-looking statements.
Company contact:
Mr. Y. Tristan Kuo
Chief Financial Officer
China Biologic Products, Inc.
Telephone: +86 53 8620 2206
Email: IR@chinabiologic.com
SOURCE China Biologic Products, Inc.